References

1. (1985). Guanidines.
2. Clifford Bailey,Caroline Day (1989). Traditional Plant Medicines as Treatments for Diabetes.
3. Clifford Bailey (1992). Biguanides and NIDDM.
4. H Leclerc,Le Galega (1928). Unknown Title.
5. J Duke (2002). Handbook of medicinal herbs.
6. H Muller,H Rheinwein (1927). Pharmacology of galegin.
7. F Bischoff,M Sahyun,M Long (2017). Guanidine Structure and Hypoglycemia.
8. G Ungar,L Freedman,S Shapiro (1957). Pharmacological Studies of a New Oral Hypoglycemic Drug.
9. H Mehnert,W Seitz (1958). Weitere Ergebnisse der diabetesbehandlung mit blutzuckersenkenden biguaniden.
10. Jorge Mestman,M Dean,S Pocock,M,Arthur Kirchner,M Los,Angeles (1969). Lactic Acidosis with Recovery In Diabetes Mellitus On Phenformin Therapy.
11. C William,Gong,B Donald,Kato Phenformin Induced Lactic Acidosis.
12. M Nattrass,K Alberti,Biguanides (1978). Unknown Title.
13. J Sterne (1969). Oral Hypoglycaemic Agents.
14. L Hermann (1979). Metformin: a review of history, pharmacodynamics and therapy.
15. Clifford Bailey,Robert Turner (1996). Metformin.
16. Meiter Ch,Bodmer M (2008). Metformin, sulfonylureas, or other antidiabetes drugs and the risk of lactic acidosis or hypoglycemia.
17. American Diabetes,Association (2002). Implication of the united kingdome prospective diabetes study.
18. El-Bayouki Kh,R Abdel-Rahman (2016). Synthesis and evaluation of 1-substituted-biguanide derivates as anti-diabetic agents for type II diabetes Insulin Resistant.
19. Seymour Shapiro,Vincent Parrino,Elaine Rogow,Louis Freedman (1959). Hypoglycemic Agents. II.^1—3 Arylbiguanides.
20. A Shalmalshi (2008). New Route to Metformin Hydrochloride (N,N-dimethylimidodicarbonimidic diamide hydrochloride) Synthesis.
21. John Scarpello,Harry Howlett (2008). Metformin therapy and clinical uses.
22. S Inzucchi,R Bergenstal,J Buse,M Diamant,E Ferrannini,M Nauck (2012). Management of hyperglycemia in type 2 diabetes: A patient centered approach: Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).
23. Nicolas Michael,F Hirshman (2002). Metformin Increases AMP-Activated Protein Kinase Activity in Skeletal Muscle of Subjects with Type 2.
24. Mengwei Zang,Adriana Zuccollo,Xiuyun Hou,Daisuke Nagata,Kenneth Walsh,Haya Herscovitz,Peter Brecher,Neil Ruderman,Richard Cohen (2004). AMP-activated Protein Kinase Is Required for the Lipid-lowering Effect of Metformin in Insulin-resistant Human HepG2 Cells.
25. Mohamad-Yehia El-Mir,Véronique Nogueira,Eric Fontaine,Nicole Avéret,Michel Rigoulet,Xavier Leverve (2000). Dimethylbiguanide Inhibits Cell Respiration via an Indirect Effect Targeted on the Respiratory Chain Complex I.
26. Arian Emami Riedmaier,Pascale Fisel,Anne Nies,Elke Schaeffeler,Matthias Schwab (2013). Metformin and cancer: from the old medicine cabinet to pharmacological pitfalls and prospects.
27. X Leverve,B Guigas,D Detaille,C Batandier,E Koceir,C Chauvin (2003). Mitochondrial metabolism and type2 diabetes: A specific target of metformin.
28. A Halestrap,Owen M (2000). Evidence that metformin exerts its anti-diabetic effects through inhibition of complex 1 of the mitochondrial respiratory chain.
29. X Leverve,B Guigas,D Detaille,C Batandier,E Koceir,C Chauvin,E Fontaine,N Wiernsperger (2003). Mitochondrial metabolism and type-2 diabetes: a specific target of metformin.
30. R Miller,Q Chu,J Xie,M Foretz,B Viollet,M Birnbaum (2013). Biguanides suppress hepatic glucagon signalling by decreasing production of cyclic AMP.
31. Benoit Viollet,Bruno Guigas,Nieves Garcia,Jocelyne Leclerc,Marc Foretz,Fabrizio Andreelli (2012). Cellular and molecular mechanisms of metformin: an overview.
32. Paul Caton,Nanda Nayuni,Julius Kieswich,Noorafza Khan,Muhammed Yaqoob,Roger Corder (2010). Metformin suppresses hepatic gluconeogenesis through induction of SIRT1 and GCN5.
33. Ling He,Amin Sabet,Stephen Djedjos,Ryan Miller,Xiaojian Sun,Mehboob Hussain,Sally Radovick,Fredric Wondisford (2009). Metformin and Insulin Suppress Hepatic Gluconeogenesis through Phosphorylation of CREB Binding Protein.
34. M Foretz,S Hébrard,J Leclerc,E Zarrinpashneh,M Soty,G Mithieux (2010). Metformin inhibits hepatic gluconeogenesis in mice independently of the LKB1/AMPK pathway via a decrease in hepatic energy state.
35. A Scheen (1996). Clinical pharmacokinetics of metformin.
36. J Arora,M Day,R Doogue,M Duong,J (2011). Clinical pharmacokinetics of metformin.
37. (2011). Summary of Revisions to the 2011 Clinical Practice Recommendations.
38. Robert Turner,C Cull,V Frighi,R Holman (1999). Glycemic Control With Diet, Sulfonylurea, Metformin, or Insulin in Patients With Type 2 Diabetes Mellitus<SUBTITLE>Progressive Requirement for Multiple Therapies (UKPDS 49)</SUBTITLE>.
39. Harry Howlett,Clifford Bailey (1999). A Risk-Benefit Assessment of Metformin in Type 2 Diabetes Mellitus.
40. S Inzucchi,R Bergenstal,J Buse,M Diamant,E Ferrannini,M Nauck (2012). Management of hyperglycaemia in type 2 diabetes: a patientcentered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).
41. W Bennett,N Maruthur,S Singh,J Segal,L Wilson,R Chatterjee (2011). Comparative effectiveness and safety of medications for type 2 diabetes: an update including new drugs and 2drug combinations.
42. P Raskin (2008). Oral combination therapy: repaglinide plus metformin for treatment of type 2 diabetes.
43. Bernard Charbonnel,Avraham Karasik,Ji Liu,Mei Wu,Gary Meininger (2006). Efficacy and Safety of the Dipeptidyl Peptidase-4 Inhibitor Sitagliptin Added to Ongoing Metformin Therapy in Patients With Type 2 Diabetes Inadequately Controlled With Metformin Alone.
44. John Gerich,Philip Raskin,Lisa Jean-Louis,Das Purkayastha,Michelle Baron (2005). PRESERVE-β.
45. M González-Ortiza,J Guerrero-Romero,Violante Ortiz,R (2009). Efficacy of glimepiride/metformin combination versus glibenclamide/metformin in patients with uncontrolled type 2 diabetes mellitus.
46. L Tock,A Dˆamaso,A De Piano,J Carnier (2010). Long-Term Effects of metformin and lifestyle modification on nonalcoholic fatty liver disease obese adolescents.
47. Min Park,Sanjay Kinra,Kirsten Ward,Billy White,Russell Viner (2009). Metformin for Obesity in Children and Adolescents: A Systematic Review.
48. Lawrence Blonde,George Dailey,Serge Jabbour,Charles Reasner,Donna Mills (2004). Gastrointestinal tolerability of extended-release metformin tablets compared to immediate-release metformin tablets: results of a retrospective cohort study.
49. Juliana Levy,Roberta Cobas,Marília Gomes (2010). Assessment of efficacy and tolerability of once-daily extended release metformin in patients with type 2 diabetes mellitus.
50. I Raz,I Delaet,H Goyvaerts (2000). Safety and efficacy of novel extended release formulation of metformin in patients with type 2 diabetes.
51. Jeffrey Johnson,Sumit Majumdar,Scot Simpson,Ellen Toth (2002). Decreased Mortality Associated With the Use of Metformin Compared With Sulfonylurea Monotherapy in Type 2 Diabetes.
52. A; Scheen,N Paquot (2013). Metformin revisited: A critical review of the benefit–risk balance in at-risk patients with type 2 diabetes.
53. D Hulisz,M Bonfiglio,R Murray (1998). Metformin-Associated Lactic Acidosis.
54. Diabetes Uk Prospective,( Study,Ukpds) Group (1998). Effect of intensive blood glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34).
55. (1998). UKPDS) Group: Effect of intensive blood glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34).
56. D Giugliano,A Quatraro,G Consoli,A Minei,A Ceriello,N De Rosa,F D'onofrio (1993). Metformin for obese, insulin-treated diabetic patients: improvement in glycaemic control and reduction of metabolic risk factors.
57. S Vella,L Buetow,P Royle,S Livingstone,H Colhoun,J Petrie (2010). The use of metformin in type 1 diabetes: a systematic review of efficacy.
58. S Abdelghaffar,A Attia (2009). Metformin added to insulin therapy for type 1 diabetes mellitus in adolescents.
59. S Wiegand,U Maikowski,O Blankenstein,H Bierbermann,P Tarnow,A Grutes (2004). Type 2 diabetes and impaired glucose tolerance in European children and adolescents with obesity-a problem that is no longer restrited to minority groups.
60. Orit Pinhas-Hamiel,Phil Zeitler (2007). Clinical presentation and treatment of type 2 diabetes in children.
61. Kenneth Jones,Silva Arslanian,Valentina Peterokova,Jong-Soon Park,Mark Tomlinson (2002). Effect of Metformin in Pediatric Patients With Type 2 Diabetes.
62. Stefano Palomba,Angela Falbo,Fulvio Zullo,Francesco Orio (2009). Evidence-Based and Potential Benefits of Metformin in the Polycystic Ovary Syndrome: A Comprehensive Review.
63. M Balasubramanyam (2014). Metformin: Nature′s gift that keeps on giving more!.
64. Vladimir Anisimov (2013). Metformin: Do we finally have an anti-aging drug?.
65. M Yin,J Zhou,E Gorak,F Quddus (2013). Metformin is associated with survival benefit in cancer patients with concurrent type 2 diabetes: A systematic review and metaanalysis.
66. Diana Hatoum,Eileen Mcgowan (2015). Recent Advances in the Use of Metformin: Can Treating Diabetes Prevent Breast Cancer?.
67. Mihaela Aldea,Lucian Craciun,Ciprian Tomuleasa,Ioana Berindan-Neagoe,Gabriel Kacso,Ioan Florian,Carmen Crivii (2014). Repositioning metformin in cancer: genetics, drug targets, and new ways of delivery.
68. M Krempf,K Parhofer,G Steg (2002). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Final Report.
69. Adriaan Kooy,Jolien De Jager,Philippe Lehert,Daniël Bets,Michiel Wulffelé,Ab Donker,Coen Stehouwer (2009). Long-term Effects of Metformin on Metabolism and Microvascular and Macrovascular Disease in Patients With Type 2 Diabetes Mellitus.
70. C Vitale,G Mercuro,A Cornoldi,M Fini (2005). Metformin improves endothelial function in patients with metabolic syndrome.
71. Miloš Spasić,Patrick Callaerts,Koenraad Norga (2009). AMP-Activated Protein Kinase (AMPK) Molecular Crossroad for Metabolic Control and Survival of Neurons.
72. Lars Van Der Heide,Geert Ramakers,Marten Smidt (2006). Insulin signaling in the central nervous system: Learning to survive.
73. Thomas Sulkin,Deborah Bosman,Andrew Krentz (1997). Contraindications to Metformin Therapy in Patients With NIDDM.
74. J Evans,S Ogston,A Emslie-Smith,A Morris (2006). Risk of mortality and adverse cardiovascular outcomes in type 2 diabetes: a comparison of patients treated with sulfonylureas and metformin.
75. Peter Lurie,Joshua Sharfstein (2006). Product Approval and Public Health at the US Food and Drug Administration.
76. Amy Calabrese,Kim Coley,Stacey Dapos,Dennis Swanson,R Rao (2002). Evaluation of Prescribing Practices.
77. Kasia Lipska,Clifford Bailey,Silvio Inzucchi (2011). Use of Metformin in the Setting of Mild-to-Moderate Renal Insufficiency.
78. A Frid,G Sterner,M Londahl (2010). Novel assay of metformin levels in patients with type 2 diabetes mellitus and varying levels of renal function.
79. J Jager,A Kooy,P Lehert,M Wulffelé (2010). Long term treatment with metformin in patients with type 2 diabetes and risk of vitamin B-12 deficiency: randomized placebo controlled trial.
80. Wei Ting,R Szeto,C Chan,M Ma,K (2006). Risk Factors of Vitamin B12 Deficiency in Patients Receiving Metformin.
81. Lilian Rojas,Marilia Gomes (2013). Metformin: an old but still the best treatment for type 2 diabetes.
82. (2003). Glucophage..
83. Leland Gershell (2005). Type 2 diabetes market.